Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy Subjects

NCT04715997 is registered in ClinicalTrials.gov with Genexine, Inc. as lead sponsor.

NCT NCT04715997
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04715997 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy Subjects
Lead sponsor
Genexine, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
December 30, 2020
Completion date
April 19, 2022
Enrollment
185 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2